tirzepatide back on shortage list Mounjaro will remain off after FDA review FDA says the tirzepatide weight-loss

Restrictions: Must sign waiver

Review of concurrent medications to identify potential drug interactions or cumulative side effects Assessment of nutritional intake and consideration of referral to a dietitian for specialist advice In some cases, your healthcare team may recommend adjusting your GLP-1 dose , switching to an alternative GLP-1 medication, or modifying other diabetes medications to optimise your treatment whilst minimising side effects

Beyond BMI: Consider metabolic health, historical weight, and GLP-1 usage rather than just current BMI

You are close but do not meet the comorbidity pathway threshold of 27